Inhibitors of B-cell receptor signaling for patients with B-cell malignancies

Cancer Journal (United States)

Volumn 18, Issue 5, 2012, Pages 404-410

  Choi, Michael Y ^a   Kipps, Thomas J ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

AVL 292; B cell receptor; Bruton's tyrosine kinase; GS 1101; PCI 32765; PI3K; Syk

Indexed keywords

AVL 292; B LYMPHOCYTE RECEPTOR; BENDAMUSTINE; BRUTON TYROSINE KINASE INHIBITOR; FOSTAMATINIB; IBRUTINIB; IDELALISIB; OFATUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PICEATANNOL; PROTEIN KINASE SYK INHIBITOR; RITUXIMAB; SORAFENIB; UNCLASSIFIED DRUG;

AMINOTRANSFERASE BLOOD LEVEL; APOPTOSIS; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; CELL EXPANSION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CYTOPENIA; DIARRHEA; DRUG HALF LIFE; DRUG MECHANISM; ECCHYMOSIS; FATIGUE; FOLLICULAR LYMPHOMA; HUMAN; HYPERTENSION; INFECTION; LARGE CELL LYMPHOMA; LYMPHOCYTE COUNT; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RASH; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN INFECTION; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION;

HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, MANTLE-CELL; NEOPLASM STAGING; NIACINAMIDE; OXAZINES; PHENYLUREA COMPOUNDS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN-TYROSINE KINASES; PURINES; PYRAZOLES; PYRIDINES; PYRIMIDINES; QUINAZOLINONES; RECEPTORS, ANTIGEN, B-CELL; SIGNAL TRANSDUCTION;

EID: 84866920827     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e31826c5810     Document Type: Review

References (81)

1. Hashimoto S, Chiorazzi N, Gregersen PK. The complete sequence of the human CD79b (Ig beta/B29) gene: identification of a conserved exon/ intron organization, immunoglobulin-like regulatory regions, and allelic polymorphism. Immunogenetics. 1994;40:145-149.
2. Hashimoto S, Mohrenweiser HW, Gregersen PK, et al. Chromosomal localization, genomic structure, and allelic polymorphism of the human CD79 alpha (Ig-alpha/mb-1) gene. Immunogenetics. 1994;40:287-295.
3. Clark MR, Campbell KS, Kazlauskas A, et al. The B cell antigen receptor complex: association of Ig-alpha and Ig-beta with distinct cytoplasmic effectors. Science. 1992;258:123-126.
4. Brezski RJ, Monroe JG. B-cell receptor. Adv Exp Med Biol. 2008;640: 12-21.
5. Gaul BS, Harrison ML, Geahlen RL, et al. Substrate recognition by the Lyn protein-tyrosine kinase. NMR structure of the immunoreceptor tyrosine-based activation motif signaling region of the B cell antigen receptor. J Biol Chem. 2000;275:16174-16182.
6. Baba Y, Hashimoto S,MatsushitaM, et al. BLNK mediates Syk-dependent Btk activation. Proc Natl Acad Sci U S A. 2001;98:2582-2586.
7. Kabak S, Skaggs BJ, Gold MR, et al. The direct recruitment of BLNK to immunoglobulin alpha couples the B-cell antigen receptor to distal signaling pathways. Mol Cell Biol. 2002;22:2524-2535.
8. Mohamed AJ, Yu L, Backesjo CM, et al. Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. Immunol Rev. 2009;228:58-73.
9. Tomlinson MG, Woods DB, McMahon M, et al. A conditional form of Bruton's tyrosine kinase is sufficient to activate multiple downstream signaling pathways via PLC gamma 2 in B cells. BMC Immunol. 2001;2:4.
10. de Rooij MF, Kuil A, Geest CR, et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptorY and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood. 2012;119: 2590-2594.
11. Halcomb KE, Musuka S, Gutierrez T, et al. Btk regulates localization, in vivo activation, and class switching of anti-DNA B cells. Mol Immunol. 2008;46:233-241.
12. Lee KG, Xu S, Kang ZH, et al. Bruton's tyrosine kinase phosphorylates Toll-like receptor 3 to initiate antiviral response. Proc Natl Acad Sci U S A. 2012;109:5791-5796.
13. James RG, Biechele TL, Conrad WH, et al. Bruton's tyrosine kinase revealed as a negative regulator of Wnt-beta-catenin signaling. Sci Signal. 2009;2:ra25.
14. Buggy JJ, Elias L. Bruton tyrosine kinase (BTK) and its role in B-cell malignancy. Int Rev Immunol. 2012;31:119-132.
15. Johnson AJ, Herman SE. Molecular pathways: targeting the phosphoinositide 3-kinase (PI3-kinase) p110 delta in chronic lymphocytic leukemia. Clin Cancer Res. 2012;18:4013-4018.
16. Beckwith M, Jorgensen G, Longo DL. The protein product of the protooncogene c-cbl forms a complex with phosphatidylinositol 3-kinase p85 and CD19 in anti-IgMYstimulated human B-lymphoma cells. Blood. 1996;88:3502-3507.
17. Inabe K, Kurosaki T. Tyrosine phosphorylation of B-cell adaptor for phosphoinositide 3-kinase is required for Akt activation in response to CD19 engagement. Blood. 2002;99:584-589.
18. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007;129:1261-1274.
19. Fruman DA, Ferl GZ, An SS, et al. Phosphoinositide 3-kinase and Bruton's tyrosine kinase regulate overlapping sets of genes in B lymphocytes. Proc Natl Acad Sci U S A. 2002;99:359-364.
20. Okkenhaug K, Ali K, Vanhaesebroeck B. Antigen receptor signalling: a distinctive role for the p110delta isoform of PI3K. Trends Immunol. 2007;28:80-87.
21. Fruman DA, Rommel C. PI3Kdelta inhibitors in cancer: rationale and serendipity merge in the clinic. Cancer Discov. 2011;1:562-572.
22. Kipps TJ. The B-cell receptor and ZAP-70 in chronic lymphocytic leukemia. Best Pract Res Clin Haematol. 2007;20:415-424.
23. Gupta N, Scharenberg AM, Fruman DA, et al. The SH2 domain-containing inositol 5¶-phosphatase (SHIP) recruits the p85 subunit of phosphoinositide 3-kinase during FcgammaRIIb1-mediated inhibition of B cell receptor signaling. J Biol Chem. 1999;274:7489-7494.
24. Gay D, Saunders T, Camper S, et al. Receptor editing: an approach by autoreactive B cells to escape tolerance. J Exp Med. 1993;177: 999-1008.
25. Ghia EM, Jain S, Widhopf GF 2nd, et al. Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection. Blood. 2008;111:5101-5108.
26. Rowland SL, Leahy KF, Halverson R, et al. BAFF receptor signaling aids the differentiation of immature B cells into transitional B cells following tonic BCR signaling. J Immunol. 2010;185:4570-4581.
27. Pelanda R, Torres RM. Central B-cell tolerance: where selection begins. Cold Spring Harb Perspect Biol. 2012;4:a007146.
28. Reichman-Fried M, Hardy RR, Bosma MJ. Development of B-lineage cells in the bone marrow of scid/scid mice following the introduction of functionally rearranged immunoglobulin transgenes. Proc Natl Acad Sci U S A. 1990;87:2730-2734.
29. Young F, Ardman B, Shinkai Y, et al. Influence of immunoglobulin heavyand light-chain expression on B-cell differentiation. Genes Dev. 1994;8: 1043-1057.
30. Suarez F, Lortholary O, Hermine O, et al. Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood. 2006;107:3034-3044.
31. Nakamura S, Sugiyama T, Matsumoto T, et al. Long-termclinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan. Gut. 2012;61:507-513.
32. Craig VJ, Cogliatti SB, Arnold I, et al. B-cell receptor signaling and CD40 ligandYindependent T cell help cooperate in Helicobacter-induced MALT lymphomagenesis. Leukemia. 2010;24:1186-1196.
33. Yan Q, Huang Y,Watkins AJ, et al. BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas. Haematologica. 2012;97:595-598.
34. Stevenson FK, Krysov S, Davies AJ, et al. B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2011;118:4313-4320.
35. Messmer BT, Albesiano E, Efremov DG, et al. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J Exp Med. 2004;200:519-525.
36. Widhopf GFn, Rassenti LZ, Toy TL, et al. Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins. Blood. 2004;104:2499-2504.
37. Stamatopoulos K, Belessi C, Moreno C, et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood. 2007;109:259-270.
38. Herishanu Y, Perez-Galan P, Liu D, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood. 2011;117: 563-574.
39. Muzio M, Apollonio B, Scielzo C, et al. Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy. Blood. 2008;112:188-195.
40. Petlickovski A, Laurenti L, Li X, et al. Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells. Blood. 2005;105:4820-4827.
41. Guarini A, Chiaretti S, Tavolaro S, et al. BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgV H unmutated chronic lymphocytic leukemia (CLL) cells. Blood. 2008;112:782-792.
42. Chen L, Huynh L, Apgar J, et al. ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia. Blood. 2008;111:2685-2692.
43. Rassenti LZ, Jain S, Keating MJ, et al. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood. 2008;112:1923-1930.
44. Pighi C, Gu TL, Dalai I, et al. Phospho-proteomic analysis of mantle cell lymphoma cells suggests a pro-survival role of B-cell receptor signaling. Cell Oncol (Dordr). 2011;34:141-153.
45. Boyd RS, DyerMJ, Cain K. Proteomic analysis of B-cell malignancies. J Proteomics. 2010;73:1804-1822.
46. Sweetenham JW. Molecular signatures in the diagnosis and management of diffuse large B-cell lymphoma. Curr Opin Hematol. 2011;18:288-292.
47. Lenz G, Davis RE, Ngo VN, et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science. 2008;319:1676-1679.
48. Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463:88-92.
49. Kloo B,NagelD, PfeiferM, et al.Critical role of PI3Ksignaling for NF-kappaBYdependent survival in a subset of activated B-cellYlike diffuse large B-cell lymphoma cells. Proc Natl Acad Sci U S A. 2011;108:272-277.
50. Juszczynski P, Chen L, O'Donnell E, et al. BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt. Blood. 2009;114:5315-5321.
51. Chen L, Monti S, Juszczynski P, et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood. 2008;111:2230-2237.
52. Cheson BD, Byrd JC, Rai KR, et al. Novel targets agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol. 2012;10;30:2820-2822.
53. Suljagic M, Longo PG, Bennardo S, et al. The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Emu-TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling. Blood. 2010;116:4894-4905.
54. Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010;115: 2578-2585.
55. Genovese MC, Kavanaugh A, Weinblatt ME, et al. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum. 2011;63:337-345.
56. Hoellenriegel J, Coffey GP, Sinha U, et al. Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. Leukemia. 2012.26:1576-1583.
57. Lannutti BJ, Meadows SA, Herman SE, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 2011;117:591-594.
58. Herman SE, Gordon AL,Wagner AJ, et al. Phosphatidylinositol 3-kinasedelta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood. 2010;116:2078-2088.
59. Hoellenriegel J, Meadows SA, Sivina M, et al. The phosphoinositide 3¶-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 2011;118:3603-3612.
60. Furman RR, Byrd JC, Flinn IW, et al. Interim results from a phase I study of CAL-101, a selective oral inhibitor of phosphatidylinositol 3-kinase p110d isoform, in patients with relapsed or refractory hematologic malignancies. J Clin Oncol. 2010;28. Abstract 3032.
61. Kahl BS, Byrd JC, Flinn IW. Significant clinical activity of CAL-101, an isoform-selective inhibitor of phosphatidylinositol-3 kinase p110delta in patients with relapsed or refractory indolent and mantle cell lymphoma [abstract]. Ann Oncol. 2011;22. Abstract 350.
62. Coutre SE, Byrd JC, Brown JR, et al. Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110d, in patients with previously treated chronic lymphocytic leukemia. J Clin Oncol. 2011;29. Abstract 6631.
63. Sharman J, de Vos S, Leonard JP, et al. A phase 1 study of the selective phosphatidylinositol 3-kinase delta inhibitor, CAL-101 (GS-1101), in combination with rituximab and/or bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia. ASH Annu Meeting Abstr. 2011;118:1787.
64. Flinn IW, Schreeder MT, Wagner-Johnston ND, et al. A phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110d, in combination with rituximab and/or bendamustine in patients with relapsed or refractory B-cell malignancies. ASH Annu Meeting Abstr. 2010;116:2832.
65. Furman RR, Barrientos JC, Sharman J, et al. A phase I/II study of the selective phosphatidylinositol 3-kinase delta inhibitor GS-1101 (CAL-101) with ofatumumab in patients with previously treated chronic lymphocytic leukemia. J Clin Oncol. 2012;30. Abstract 6518.
66. Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010;107:13075-13080.
67. Advani R, Sharman J, Smith SM, et al. Effect of Btk Inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: evidence of antitumor activity from a phase I study. J Clin Oncol. 2010;28:15s. Abstract 8012.
68. Ponader S, Chen SS, Buggy JJ, et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012;119:1182-1189.
69. O'Brien S, Burger JA, Blum KA, et al. The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 induces durable responses in relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL/SLL): follow-up of a phase Ib/II study. ASH Annu Meeting Abstr. 2011;118:983.
70. Wang L, Marin P, Blum KA, et al. The Bruton's tyrosine kinase inhibitor PCI-32765 is highly active as single-agent therapy in previously-treated mantle cell lymphoma (MCL): preliminary results of a phase II trial. ASH Annu Meeting Abstr. 2011;118:442.
71. Byrd JC, Furman RR, Coutre SE, et al. The Bruton's tyrosine kinase inhibitor PCI-32765 in treatment-naive chronic lymphocytic leukemia patients: interim results of a phase Ib/II study. J Clin Oncol. 2012;30. Abstract 6507.
72. Chang B, Francesco M, Magadala P, et al. Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor, PCI-32765, in mantle cell lymphoma patients. ASH Annu Meeting Abstr. 2011;118:954.
73. Jaglowski S, Jones JA, Flynn J, et al. A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and related diseases. J Clin Oncol. 2012;30. Abstract 6508.
74. Staudt LM, Dunleavy K, Buggy JJ, et al. The Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 modulates chronic active BCR signaling and induces tumor regression in relapsed/refractory ABC DLBCL. ASH Annu Meeting Abstr. 2011;118:2716.
75. Evans E, Tester R, Aslanian S, et al. Clinical development of AVL-292; a potent, selective covalent Btk inhibitor for the treatment of B cell malignancies. ASH Annu Meeting Abstr. 2011;118:3485.
76. Brown JR, Sharman J, Harb WA, et al. Phase Ib trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase, in chronic lymphocytic leukemia and BYnon-Hodgkin lymphoma. J Clin Oncol. 2012;30. Abstract 8032.
77. Tordai A, Franklin RA, Patel H, et al. Cross-linking of surface IgM stimulates the Ras/Raf-1/MEK/MAPK cascade in human B lymphocytes. J Biol Chem. 1994;269:7538-7543.
78. Messmer D, Fecteau JF, O'Hayre M, et al. Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib. Blood. 2011;117: 882-889.
79. Fecteau JF, Bharati IS, O'Hayre M, et al. Sorafenib-induced apoptosis of chronic lymphocytic leukemia cells is associated with downregulation of RAF and myeloid cell leukemia sequence 1 (Mcl-1). Mol Med. 2012; 18:19-28.
80. Andersen JN, Sathyanarayanan S, Di Bacco A, et al. Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors. Sci Transl Med. 2010;2:43ra55.
81. Yang Y, Shaffer AL, Emre NC, et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell. 2012; 21:723-737.